Publicité
English Flag
Biotech Finances - L'information stratégique des biodécideurs et des bioinvestisseurs
RECHERCHER SUR LE SITE
ET DANS LES ARCHIVES
jeudi 23 mai 2013
 Mémoriser  
 
 

Communiqué de Presse

Research and Markets: Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides

Le 01/06/2012 à 17:06

June 1, 2012 15:53 UTC

Research and Markets: Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/pjcf9l/triple_analysis_c) has announced the addition of the "Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides" report to their offering.

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

- Supporting development of integrative molecule, pathway and disease area strategies

- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

For more information visit http://www.researchandmarkets.com/research/pjcf9l/triple_analysis_c.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Oncology


Source: Research and Markets